240 related articles for article (PubMed ID: 26138905)
21. [GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Reinhardt D; Reinhardt K; Neuhoff C; Sander A; Klusmann JH; Pekrun A; Sauerbrey A; von Stackelberg A; Rössig C; Creutzig U; Kolenova A
Klin Padiatr; 2012 Apr; 224(3):153-5. PubMed ID: 22513796
[TBL] [Abstract][Full Text] [Related]
22. Perturbation of fetal hematopoiesis in a mouse model of Down syndrome's transient myeloproliferative disorder.
Birger Y; Goldberg L; Chlon TM; Goldenson B; Muler I; Schiby G; Jacob-Hirsch J; Rechavi G; Crispino JD; Izraeli S
Blood; 2013 Aug; 122(6):988-98. PubMed ID: 23719302
[TBL] [Abstract][Full Text] [Related]
23. Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.
Kirsammer G; Jilani S; Liu H; Davis E; Gurbuxani S; Le Beau MM; Crispino JD
Blood; 2008 Jan; 111(2):767-75. PubMed ID: 17901249
[TBL] [Abstract][Full Text] [Related]
24. Clinical, cytogenetic, and molecular analyses of 17 neonates with transient abnormal myelopoiesis and nonconstitutional trisomy 21.
Yuzawa K; Terui K; Toki T; Kanezaki R; Kobayashi A; Sato T; Kamio T; Kudo K; Sasaki S; Endo M; Ozono S; Nomura K; Ito E
Pediatr Blood Cancer; 2020 Apr; 67(4):e28188. PubMed ID: 32020774
[TBL] [Abstract][Full Text] [Related]
25. Transient leukemia (transient myeloproliferative disorder, transient abnormal myelopoiesis) of Down syndrome.
Brink DS
Adv Anat Pathol; 2006 Sep; 13(5):256-62. PubMed ID: 16998319
[TBL] [Abstract][Full Text] [Related]
26. Development of acute megakaryoblastic leukemia from a minor clone in a Down syndrome patient with clinically overt transient myeloproliferative disorder.
Xu G; Kato K; Toki T; Takahashi Y; Terui K; Ito E
J Pediatr Hematol Oncol; 2006 Oct; 28(10):696-8. PubMed ID: 17023834
[TBL] [Abstract][Full Text] [Related]
27. Molecular insights into Down syndrome-associated leukemia.
Vyas P; Crispino JD
Curr Opin Pediatr; 2007 Feb; 19(1):9-14. PubMed ID: 17224656
[TBL] [Abstract][Full Text] [Related]
28. Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome.
Inaba H; Londero M; Maurer SH; Onciu M; Ge Y; Taub JW; Rubnitz JE; Raimondi SC
J Clin Oncol; 2011 Mar; 29(9):e230-3. PubMed ID: 21205752
[No Abstract] [Full Text] [Related]
29. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Kimura R; Kamino K; Yamamoto M; Nuripa A; Kida T; Kazui H; Hashimoto R; Tanaka T; Kudo T; Yamagata H; Tabara Y; Miki T; Akatsu H; Kosaka K; Funakoshi E; Nishitomi K; Sakaguchi G; Kato A; Hattori H; Uema T; Takeda M
Hum Mol Genet; 2007 Jan; 16(1):15-23. PubMed ID: 17135279
[TBL] [Abstract][Full Text] [Related]
30. Are GATA1 mutations occurring at random in Down syndrome transient leukemia?
Satgé D
Med Hypotheses; 2014 Aug; 83(2):154-9. PubMed ID: 24880866
[TBL] [Abstract][Full Text] [Related]
31. [Transient myeloproliferative disorder in a neonate without Down syndrome].
Adam M; Vincenot A; Gouraud F; Harvel C; Perot C; Portnoi MF; Andre-Kerneis E; Giraudier S; Leverger G; Favier R
Ann Biol Clin (Paris); 2007; 65(5):569-73. PubMed ID: 17913678
[TBL] [Abstract][Full Text] [Related]
32. Transient myeloproliferative disorder in neonates with and without Down syndrome: a tale of 2 syndromes.
Apollonsky N; Shende A; Ouansafi I; Brody J; Atlas M; Aygun B
J Pediatr Hematol Oncol; 2008 Nov; 30(11):860-4. PubMed ID: 18989165
[TBL] [Abstract][Full Text] [Related]
33. Transient neonatal myeloproliferative disorder without Down syndrome and detection of GATA1 mutation.
Magalhães IQ; Splendore A; Emerenciano M; Córdoba MS; Córdoba JC; Allemand PA; Ferrari I; Pombo-de-Oliveira MS
J Pediatr Hematol Oncol; 2005 Jan; 27(1):50-2. PubMed ID: 15654280
[TBL] [Abstract][Full Text] [Related]
34. Down syndrome and GATA1 mutations in transient abnormal myeloproliferative disorder: mutation classes correlate with progression to myeloid leukemia.
Kanezaki R; Toki T; Terui K; Xu G; Wang R; Shimada A; Hama A; Kanegane H; Kawakami K; Endo M; Hasegawa D; Kogawa K; Adachi S; Ikeda Y; Iwamoto S; Taga T; Kosaka Y; Kojima S; Hayashi Y; Ito E
Blood; 2010 Nov; 116(22):4631-8. PubMed ID: 20729467
[TBL] [Abstract][Full Text] [Related]
35. Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome.
Ng AP; Hyland CD; Metcalf D; Carmichael CL; Loughran SJ; Di Rago L; Kile BT; Alexander WS
Blood; 2010 May; 115(19):3966-9. PubMed ID: 20007548
[TBL] [Abstract][Full Text] [Related]
36. Distinct GATA1 Point Mutations in Monozygotic Twins With Down Syndrome and Transient Abnormal Myelopoiesis From a Triplet Pregnancy: A Case Report and Review of Literature.
Yin L; Lovell MA; Wilson ML; Wei Q; Liang X
Am J Clin Pathol; 2016 Dec; 146(6):753-759. PubMed ID: 28028114
[TBL] [Abstract][Full Text] [Related]
37. Mutation of the AML1/RUNX1 gene in a transient myeloproliferative disorder patient with Down syndrome.
Taketani T; Taki T; Takita J; Ono R; Horikoshi Y; Kaneko Y; Sako M; Hanada R; Hongo T; Hayashi Y
Leukemia; 2002 Sep; 16(9):1866-7. PubMed ID: 12200707
[No Abstract] [Full Text] [Related]
38. Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis.
Mundschau G; Gurbuxani S; Gamis AS; Greene ME; Arceci RJ; Crispino JD
Blood; 2003 Jun; 101(11):4298-300. PubMed ID: 12560215
[TBL] [Abstract][Full Text] [Related]
39. Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.
Nikolaev SI; Santoni F; Vannier A; Falconnet E; Giarin E; Basso G; Hoischen A; Veltman JA; Groet J; Nizetic D; Antonarakis SE
Blood; 2013 Jul; 122(4):554-61. PubMed ID: 23733339
[TBL] [Abstract][Full Text] [Related]
40. Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Dowjat WK; Adayev T; Kuchna I; Nowicki K; Palminiello S; Hwang YW; Wegiel J
Neurosci Lett; 2007 Feb; 413(1):77-81. PubMed ID: 17145134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
